Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium chloride 5% acts as an osmotic diuretic. The hypertonic solution creates an osmotic gradient that draws water from the intracellular space into the extracellular compartment, increasing intravascular volume and promoting free water clearance. It also replaces sodium and chloride deficits.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
FDA-approved: Treatment of hyponatremia (symptomatic or severe), osmotic diuresis, and as a source of electrolytes.,Off-label: Cerebral edema, increased intracranial pressure, management of herniation syndromes, intraoperative fluid resuscitation in hyponatremic patients.
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
Intravenous infusion: 500-1000 m L as a single dose; rate varies based on patient status and indication.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
The terminal half-life of administered sodium and chloride is approximately 8–12 hours for excess free water elimination, reflecting renal clearance; for sodium ions, the half-life is highly variable and dependent on hydration status, renal function, and hormonal regulation (ADH, aldosterone). In anuric patients, half-life may extend to 24–48 hours.
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Sodium and chloride are not metabolized; they are excreted primarily by the kidneys.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Sodium and chloride ions are freely filtered by the glomerulus; >90% is reabsorbed in the renal tubules under homeostatic regulation. Fractional excretion of sodium (FENa) is typically <1% in euvolemic states. Unabsorbed ions are eliminated in urine, with negligible biliary or fecal excretion.
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Sodium and chloride ions are not protein bound; they exist as free ions in plasma.
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
Approximately 0.6–0.7 L/kg, corresponding to total body water. For sodium, the Vd approximates the extracellular fluid volume (~0.2 L/kg) because sodium is primarily extracellular; chloride distributes similarly.
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
Intravenous: 100% bioavailability. Oral: Variable; sodium and chloride are nearly completely absorbed (≥95%) via active transport and solvent drag in the small intestine.
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
Contraindicated in severe renal impairment with oliguria or anuria; use with caution and monitor fluid balance in mild to moderate impairment.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
No adjustment required; monitor sodium levels in patients with ascites or cirrhosis.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Intravenous infusion: 5-10 m L/kg/dose, administered over 2-6 hours; maximum rate 0.5-1 m Eq/kg/hour.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Use with caution due to increased risk of fluid overload and electrolyte disturbances; consider reduced infusion rates and close monitoring.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
None.
None
Risk of hypernatremia and hyperosmolality, especially in patients with renal impairment or those receiving large volumes.,Central pontine myelinolysis (osmotic demyelination) if hyponatremia is corrected too rapidly.,Infusion reactions: phlebitis, extravasation, and hypervolemia.,Use with caution in patients with heart failure, renal failure, or edema.
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hypernatremia, hyperchloremia, hypokalemia, or hyperosmolality.,Patients with fluid overload (e.g., pulmonary edema, congestive heart failure).,Severe renal impairment with oliguria or anuria.,Concurrent use of corticosteroids or corticotropin (may increase sodium retention).
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
No specific food interactions, but patients with hyponatremia should avoid excessive water intake and adhere to any fluid restrictions prescribed. A balanced diet with appropriate sodium intake as per medical advice is recommended. Avoid high-sodium processed foods if at risk of fluid overload.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Sodium chloride is a normal constituent of body fluids and is not teratogenic. No fetal risks have been associated with its administration at therapeutic doses in any trimester.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Sodium chloride is excreted into breast milk but is considered compatible with breastfeeding. The M/P ratio is not reported as it is a normal electrolyte.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
No specific dose adjustments are required for pregnancy; however, monitor for fluid retention and electrolyte disturbances as pregnancy alters fluid homeostasis.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Use with caution in patients with congestive heart failure, severe renal impairment, or hypernatremia. Monitor serum sodium levels frequently. Rapid infusion can cause fluid overload, especially in elderly or pediatric patients. In hyponatremia, correct sodium slowly (≤8-10 m Eq/L per 24 hours) to avoid osmotic demyelination. Hypertonic saline (3% or higher) is preferred for severe symptomatic hyponatremia; 5% is rarely used as it is more hyperosmolar. Ensure patency of IV access and assess for signs of extravasation due to hypertonic solution.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
This medication is a concentrated salt solution used to correct low sodium levels in your blood.,You may experience injection site pain or irritation; report any redness or swelling to your healthcare provider.,During treatment, you will have regular blood tests to monitor your sodium levels and kidney function.,Tell your doctor if you have a history of heart failure, kidney disease, or if you are on a low-salt diet.,Do not consume large amounts of salt in your diet unless directed by your doctor.,Seek immediate medical attention if you experience headache, nausea, confusion, or seizures, which may indicate rapid sodium correction.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM CHLORIDE 5% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER is a Electrolyte that works by Sodium chloride 5% acts as an osmotic diuretic. The hypertonic solution creates an osmotic gradient that draws water from the intracellular space into the extracellular compartment, increasing intravascular volume and promoting free water clearance. It also replaces sodium and chloride deficits.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM CHLORIDE 5% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM CHLORIDE 5% IN PLASTIC CONTAINER is: Intravenous infusion: 500-1000 m L as a single dose; rate varies based on patient status and indication.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining SODIUM CHLORIDE 5% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. SODIUM CHLORIDE 5% IN PLASTIC CONTAINER is classified as Category A/B. Sodium chloride is a normal constituent of body fluids and is not teratogenic. No fetal risks have been associated with its administration at therapeutic doses in any trimester.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.